Who we are
Desentum is a biopharmaceutical company based in Espoo, Finland. It is specialized in developing a novel type of allergen immunotherapy based on switching the immune system's response to allergens from hypersensitivity to tolerance by utilizing modified hypoallergens. Desentum, founded in 2011, is a spin-off company from VTT Technical Research Centre of Finland Ltd.
Our solution is an immunotherapeutic hypoallergen against allergies. We are developing products that consist of isolated, modified recombinant allergens called hypoallergens. The goal is to help the human body react differently to allergens.
Globally, allergy affects 1 billion people and the number is increasing rapidly. Allergic diseases cause significant social and economic burden such as health care costs, missed school and work days and impact on the daily lives of the patients. Our goal is to provide long-term relief for patients suffering from allergic symptoms, as well as reduce the social and economic burden allergies cause to both individuals and society.
What we are looking for
We are looking for investors and partners.